Compare APPN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | NRIX |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2017 | 2020 |
| Metric | APPN | NRIX |
|---|---|---|
| Price | $24.73 | $14.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $29.80 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 1.1M | 961.1K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,743,000.00 | $76,987,000.00 |
| Revenue This Year | $13.79 | N/A |
| Revenue Next Year | $10.56 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 28.29 | ★ 99.31 |
| 52 Week Low | $18.63 | $8.20 |
| 52 Week High | $46.06 | $22.50 |
| Indicator | APPN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 32.11 |
| Support Level | $22.39 | $11.67 |
| Resistance Level | $27.22 | $17.06 |
| Average True Range (ATR) | 1.49 | 0.90 |
| MACD | 0.46 | -0.26 |
| Stochastic Oscillator | 66.92 | 3.88 |
Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations, and also has its presence Internationally.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.